CRISPR Therapeutics poised for growth with international potential and clinical assets. Read why I rate CRSP stock a Strong ...

EPO grants new CRISPR/Cas9 patent to CVC, with broad claims covering guide RNAs and their combination with Cas9: Dublin, Ireland Friday, February 28, 2025, 14:00 Hrs [IST] ERS Gen ...

European Patent Office grants new CRISPR/Cas9 patent (EP 4 289 948) to CVC, with broad claims covering guide RNAs and their combination with Cas9. Patent strengthens CVC's leading position in ...

This is exemplified by granted US patent US11,517,582, which covers the use of CRISPR-Cas systems to achieve selective killing of bacteria by at least 1000-fold in situations where bacteria are ...

While the recent market dip has created bargains, some stocks have sufficiently lagged the market in the past year to warrant ...

The ongoing legal battles resemble other prolonged patent disputes, highlighting the challenges in monetizing groundbreaking technologies like mRNA and CRISPR. If Moderna had released ten products ...

The pharmaceutical industry remains a hub of patent innovation ... its way into clinical trials in the mid-2000s. In 2014, ...

CRISPR is a technology that can be used to edit genes and, as such, will likely change the world. The essence of CRISPR is simple: it’s a way of finding a specific bit of DNA inside a cell.

European Patent Office grants new CRISPR/Cas9 patent (EP 4 289 948) to CVC, with broad claims covering guide RNAs and their combination with Cas9. Patent strengthens CVC's leading position in European ...